The race to grab a piece of a fast-growing market for respiratory-disease vaccines intensified this week as the Food and Drug Administration on Wednesday approved Pfizer’s PFE Abrysvo, a respiratory syncytial virus vaccine for older adults.
The FDA’s nod came just weeks after the agency gave the green light to GSK’s GSK Arexvy, the first RSV vaccine approved for use in the U.S. Both vaccines are approved for adults 60 and over.
RSV…
Read the full article here
